Daniel Vasella

Last updated
Daniel Vasella
Daniel Vasella World Economic Forum 2013.jpg
Vasella in 2013
Born (1953-08-15) 15 August 1953 (age 70)
Fribourg, Switzerland
Alma mater University of Bern (MD)
OccupationBusinessman
SpouseAnne-Laurence
Children3

Daniel Lucius Vasella (born 15 August 1953) is a Swiss medical doctor, author, and executive who was CEO and chairman of the Swiss pharmaceutical company Novartis AG, the world's fifth largest drug company. [1] [2] During his tenure Novartis shares fell 10%, compared to the industry average. [3] [4] In February 2013 Vasella was awarded close to $78 million in a "golden handshake" [5]

Contents

In November 2014, Vasella was elected as a member of the board of directors at XBiotech, Inc, a biopharmaceutical company located in Austin, Texas, that focuses on the discovery and commercialization of a next generation of therapeutic antibodies which harness a human's natural immunity to fight disease. Vasella is an honorary member of the American Academy of Arts and Sciences. [6] In 2004, Time magazine named him one of the world's 100 most influential people, and he was chosen as the Most Influential European Business Leader of the Last 25 Years by the readers of the Financial Times . [1] [7] He is a former member of the steering committee of the Bilderberg Group. [8]

Early life and education

Vasella was born in Fribourg, Switzerland, in 1953. [9] His father was a history professor at the local university, and his mother was a housewife. His desire to become a doctor began during his childhood, which was marked by several tragedies. [1] [6] At eight years old, he contracted TB and meningitis and spent nearly a year in hospitals. [10] When Vasella was 13 years old, his father died from complications of surgery. [10]

Vasella obtained his M.D. in 1980 from the University of Bern in Switzerland. [9] He completed his residency at the University Hospital in Bern and the city hospital in Zurich, before returning to Bern as chief resident. [1] [9] In 1988, he changed career paths, working in the United States as a pharmaceutical sales representative and in market research. In 1989, he completed the Program for Management Development at Harvard Business School. [1] [9] Vasella was awarded an honorary doctorate for medicine by the University of Basel in 2002. [1] [6]

Career

Vasella held a number of medical positions in Switzerland before being hired in 1988 by Sandoz Pharmaceutical Corporation, the former U.S. subsidiary of Swiss pharmaceutical company, Sandoz. He remained there until 1992, when he was promoted to CEO of parent company, Sandoz Pharma Ltd., and named a member of the group executive committee. [1] [11]

Vasella helped to orchestrate the 1996 merger between Sandoz and Ciba-Geigy, another Swiss pharmaceutical company. [1] The two companies combined to form Novartis AG. Vasella was appointed CEO of the combined entity and a member of the board of directors. In 1999, he was named chairman of the board of directors. [1]

In January 2010, Vasella decided to step down as CEO. He was replaced by his hand-picked successor, Joseph Jimenez, the Division Head of Novartis Pharmaceuticals at the time.

In January 2013, Novartis announced that Vasella would be retiring as chairman of the board of directors in February 2013. [12] Vasella was named an honorary chairman, to be succeeded by Jörg Reinhard in August 2013. [13] According to the Ethos foundation Vasella earned from 2002 until 2012 312 Mio CHF from Novartis, and for the years before they estimated it to 60 Mio CHF, a total of 421 Mio CHF in 2013. That he should get 72 Mio CHF for a noncompetition clause at the end made him a public figure during the campaign for the Swiss referendum "against rip-off salaries". [14] [15] [4]

Other activities

Writing

Vasella authored Magic Cancer Bullet: How a Tiny Orange Pill May Rewrite Medical History (2003), a book about the discovery and development of the breakthrough cancer drug Gleevec. [18] The book was co-written with Robert Slater.

Personal life

Vasella met Anne-Laurence Moret, the niece of former Sandoz CFO, CEO, and chairman Marc Moret, in 1973, and they were married in 1978. [19] Vasella and his wife have two sons and a daughter. His older brother, Andrea Vasella, was a professor at the ETH Zurich. [19] Vasella is a patron of the arts and enjoys skiing and spending time outdoors. [20]

Awards and recognition

Vasella has received numerous awards including:

Related Research Articles

<span class="mw-page-title-main">Novartis</span> Swiss multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

<span class="mw-page-title-main">Pharmaceutical Research and Manufacturers of America</span> Trade group

Pharmaceutical Research and Manufacturers of America, formerly known as the Pharmaceutical Manufacturers Association, is a trade group representing companies in the pharmaceutical industry in the United States. Founded in 1958, PhRMA lobbies on behalf of pharmaceutical companies. PhRMA is headquartered in Washington, DC.

Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland. Sandoz is one of the leading global generics businesses.

<span class="mw-page-title-main">Chiron Corporation</span> American biotechnology firm (1981-2006)

Chiron Corporation was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

<span class="mw-page-title-main">Josef Ackermann</span> Swiss banker

Josef Meinrad Ackermann is a Swiss banker, former Chairman of the Bank of Cyprus, and former chief executive officer of Deutsche Bank. He has also been a member of the Washington-based financial advisory body, the Group of Thirty.

<span class="mw-page-title-main">Gedeon Richter (company)</span> Hungarian pharmaceutical company

Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest. It is the largest pharmaceutical company in Central and Eastern Europe, with an expanding direct presence in Western Europe, China, Northern America and Latin America. Richter has the largest R&D unit in Central and Eastern Europe and operations in over 100 countries.

Arthur D. Levinson is an American businessman and is the current chairman of Apple Inc. (2011–present) and CEO of Calico. He is the former chief executive officer (1995–2009) and chairman (1999–2014) of Genentech.

Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.

The Novartis Institute for Tropical Disease (NITD) was a Singapore-based tropical disease research institute created through a public-private partnership between Novartis and the Singapore Economic Development Board. Research at NITD focuses primarily on developing novel small molecule therapies for tropical infectious diseases that are endemic to the developing world, particularly dengue fever, malaria and tuberculosis.

<span class="mw-page-title-main">Klaus M. Leisinger</span> Swiss social scientist and economist (born 1947)

Klaus M. Leisinger is a social scientist and economist. He is founder and president of the Global Values Alliance in Basel. Until 2012 he was managing director and chairman of the Board of Trustees of the Novartis Foundation in Basel, Switzerland.

<span class="mw-page-title-main">Joseph Jimenez</span>

Joseph Jimenez is the former CEO of the Swiss pharmaceutical company Novartis.

<span class="mw-page-title-main">Incyte</span> American pharmaceutical company

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.

<span class="mw-page-title-main">Alex Gorsky</span> American businessman (born 1960)

Alex Gorsky is an American businessman. He is the former chairman and CEO of Johnson & Johnson. Gorsky stepped down as CEO of Johnson & Johnson in January 2022 and was succeeded by Joaquin Duato. He was the seventh person who served as the company's chairman and chief executive officer since it became a publicly traded company in 1944. He is a board director of Apple and JP Morgan Chase.

<span class="mw-page-title-main">2013 Bilderberg Conference</span>

The 2013 Bilderberg Conference took place June 6–9, 2013, at The Grove hotel in Watford, Hertfordshire, England. It was the first Bilderberg Group conference to be held in the United Kingdom since the 1998 meeting in Turnberry, Scotland.

<span class="mw-page-title-main">Pharmaceutical industry in Switzerland</span> Overview of the pharmaceutical industry in Switzerland

The pharmaceutical industry in Switzerland directly and indirectly employs about 135,000 people. It contributes 5.7% of the gross domestic product of Switzerland and 30% of the country's exports. In 2017 about 30% of Swiss exports were chemical products. In the same year Switzerland was the second largest exporter of packaged medicine in the world, with about 11% of the global total, worth $36.5 billion.

David Edmund Ian Pyott CBE was the CEO of Allergan, a pharmaceutical company from 1998 to 2015, when Allergan was acquired by Actavis. In 2014 he was one of the 25 highest-paid CEOs in the United States.

<span class="mw-page-title-main">Vasant Narasimhan</span> American doctor and CEO

Vasant "Vas" Narasimhan is an American physician and the chief executive officer of Novartis. He succeeded Joseph Jimenez who left Novartis in 2018. He briefly worked at McKinsey before joining Novartis in 2005, where he has held a range of leadership roles, including Global Head of Development for Novartis Vaccines and Global Head of Drug Development & Chief Medical Officer.

Harvey J. Berger is an American physician-scientist, entrepreneur and biotechnology executive. He was the founder and chairman and chief executive officer of ARIAD Pharmaceuticals, Inc. for 25 years, starting in 1991 and became advisor to the board in 2016. He was also executive chairman at Medinol, Inc from 2017 to 2018. In February 2018, Berger was appointed to the Dana–Farber Cancer Institute Board of Trustees.

Jörg Reinhardt has been Chairman of the Board of Directors of the Swiss pharmaceutical group Novartis AG since 2013. Since 2017, he has also been a member of the Board of Directors of the Swiss reinsurance group Swiss Re.

Deborah Dunsire is a South African medical doctor and pharmaceutical executive who has been CEO of multiple research companies.

References

  1. 1 2 3 4 5 6 7 8 9 10 Madslien, Jorn (19 January 2005). "Profile: Novartis chief Daniel Vasella". BBC News. Retrieved 15 May 2013.
  2. ↑ The Pharmaceutical Horizon Beckons, The New York Times, 13 August 2005
  3. ↑ Keiner verdiente mehr., Bilanz, 02/2013
  4. 1 2 Vasella: Das Ende der Macht, Bilanz, 2013-02-19.
  5. ↑ Novartis golden handshake angers shareholders, politicians, Reuters, 17 February 2013
  6. 1 2 3 "American Express Company Elects Dr. Daniel Vasella to Board of Directors". American Express. Archived from the original on 28 October 2012. Retrieved 15 May 2013.
  7. 1 2 The 2004 Time 100 : Daniel Vasella, Time
  8. ↑ "Former Steering Committee Members". bilderbergmeetings.org. Bilderberg Group. Archived from the original on 2014-02-02. Retrieved 2014-02-08.
  9. 1 2 3 4 "Alumni Achievement Awards – Alumni – Harvard Business School". www.alumni.hbs.edu. Retrieved 30 January 2019.
  10. 1 2 "An interview with Daniel Vasella". McKinsey & Company. Archived from the original on 28 December 2012. Retrieved 15 May 2013.
  11. ↑ "Curriculum Vitae: Dr. Daniel Vasella" (PDF). WebCite. Archived from the original (PDF) on April 25, 2012. Retrieved 15 May 2013.
  12. ↑ Businessweek : "Vasella Quitting Wins Cheers From Novartis’s Investors Archived 2013-01-27 at the Wayback Machine "
  13. ↑ Pharmaceutical Market Europe: "Bayer’s Jörg Reinhardt to replace Daniel Vasella as Novartis chair"
  14. ↑ Daniel Vasella hat bei Novartis 421 Millionen Franken verdient, Aargauer Zeitung, 2013-02-22.
  15. ↑ Vasella verhilft Abzocker-Initiative womöglich zum Sieg, NZZ, 2013-02-16.
  16. ↑ Numab appoints Daniel Vasella to Board of Directors Numab Therapeutics, press release of October 15, 2019.
  17. ↑ Global Health Program Advisory Panel Announced by Bill & Melinda Gates Foundation Bill & Melinda Gates Foundation, press release of February 2008.
  18. ↑ Vasella Slater, Daniel Robert (3 June 2003). Magic Cancer Bullet: How a Tiny Orange Pill May Rewrite Medical History. ISBN   0060010304.
  19. 1 2 "Blick für die Frau". Die Weltwoche. Retrieved 15 May 2013.
  20. ↑ "Daniel Vasella". Bloomberg Businessweek. 14 January 2002. Archived from the original on June 16, 2013. Retrieved 15 May 2013.
  21. ↑ "Alumni Achievement Awards: Daniel L. Vasella, M.D." Harvard Business School. Retrieved 15 May 2013.
  22. ↑ Cancer Research Institute, Oliver R. Grace Award.
  23. ↑ "Verleihung des Karl-Winnacker-Preises 2007 an Dr. Daniel Vasella". Philipps-Universität, Marburg. Archived from the original on 16 June 2013. Retrieved 15 May 2013.
  24. ↑ "Daniel Vasella – CEO Journals" . Retrieved 2020-04-15.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.